The Performance of Multi-tracer Multimodality PET in Lymphoma

The Performance of Multi-tracer Multimodality PET in Lymphoma

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Inclusion Criteria:

• pathologically diagnosed as lymphoma;
• Written informed consent for receiving FAPI-04 PET examinations.
• cancer planned chemotherapy or immunotherapy scheme.
• expected survival ≥ 12 weeks

Exclusion Criteria:

• cannot lie supine for half an hour;
• refuse to join the clinical researcher;
• severe liver or kidney dysfunction
• pregnancy or lactation